8-K: Humacyte Announces FDA Review Delay for ATEV, Reports Positive Phase 3 Results in Hemodialysis Access

Humacyte reports an FDA delay in the review of its ATEV for vascular trauma, while also announcing positive Phase 3 trial results for hemodialysis access and a third RMAT designation.

Summary

• Humacyte has announced that the FDA will require additional time to complete its review of the Biologics License Application (BLA) for its acellular tissue engineered vessel (ATEV) in the vascular trauma indication.
• The FDA had previously granted Priority Review for the ATEV with a PDUFA date of August 10, 2024, but now requires more time.
• Humacyte also reported positive topline results from its Phase 3 clinical trial of ATEV in hemodialysis access, showing superior functional patency compared to the standard of care.
• The company received a third Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for ATEV in advanced peripheral artery disease.
• Humacyte's second quarter 2024 financial results show no revenue, research and development expenses of $23.8 million, and a net loss of $56.7 million.
• The company's cash and cash equivalents were $93.6 million as of June 30, 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with both positive and negative developments. The FDA delay is a setback, but the positive Phase 3 results and RMAT designation are encouraging. The financial losses are concerning, but the company's cash position is relatively strong. Overall, the sentiment is neutral to slightly negative.

Positives

• The ATEV showed superior functional patency in a Phase 3 trial for hemodialysis access, indicating a potential improvement over the current standard of care.
• The FDA granted a third RMAT designation for the ATEV in advanced peripheral artery disease, highlighting its potential therapeutic value.
• Preclinical studies of the BioVascular Pancreas (BVP) showed promising results in restoring normal blood sugar in diabetic mice and islet survival in non-human primates.
• Humacyte has strengthened its board of directors with the addition of two experienced members.
• The company's cash position increased to $93.6 million as of June 30, 2024, compared to $80.4 million at the end of 2023.

Negatives

• The FDA requires additional time to complete its review of the ATEV BLA for vascular trauma, delaying the potential approval.
• Humacyte reported a significant net loss of $56.7 million for the second quarter of 2024, primarily due to a non-cash remeasurement of a contingent earnout liability.
• The company has not generated any revenue in the second quarter of 2024 or the first six months of 2024.

Risks

• The delay in FDA review of the ATEV BLA for vascular trauma introduces uncertainty regarding the approval timeline.
• The company's significant net losses and lack of revenue raise concerns about its financial sustainability.
• The company is reliant on successful clinical trials and regulatory approvals for its products.
• The company faces competition from other companies developing treatments for vascular diseases.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations.

Future Outlook

Humacyte anticipates presenting detailed results from the Phase 3 trial of ATEV in hemodialysis access at upcoming medical meetings and continues to advance its pipeline of ATEV products for various indications. The company is also working to advance its BioVascular Pancreas (BVP) program for type 1 diabetes.

Management Comments

• Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte, stated that they were surprised to be notified by the FDA that they will require additional time to complete their review of the BLA for their ATEV in vascular trauma.
• Dr. Niklason also expressed confidence in the approvability of the ATEV in treating vascular trauma, based on interactions with the FDA during the review process.
• Dr. Niklason noted that the ATEV continues to make significant progress in its other investigational indications, including in hemodialysis access.

Industry Context

The delay in FDA review highlights the challenges in bringing novel, first-in-class products to market, particularly in the field of regenerative medicine. The positive Phase 3 results in hemodialysis access and the RMAT designation for peripheral artery disease position Humacyte as a potential leader in bioengineered tissue therapies. The company's focus on multiple vascular applications and its advancements in diabetes treatment also align with broader trends in the biotechnology industry.

Comparison to Industry Standards

• The delay in the FDA review of Humacyte's ATEV for vascular trauma is not uncommon for novel biologics, as regulatory agencies often require additional time to assess complex data and manufacturing processes. Companies like Athersys and Mesoblast have also experienced delays in their regulatory approval processes for cell-based therapies.
• The positive Phase 3 results for ATEV in hemodialysis access are significant, as current standard of care, autogenous fistulas, have limitations in terms of patency and patient suitability. Companies like Vascular Graft Solutions and W. L. Gore & Associates offer alternative vascular access solutions, but Humacyte's ATEV has shown superior functional patency in this trial.
• The RMAT designation for ATEV in advanced peripheral artery disease is a positive signal, as it indicates the FDA's recognition of the potential for this therapy to address an unmet medical need. Companies like Boston Scientific and Medtronic offer devices for treating PAD, but Humacyte's ATEV is a novel approach using bioengineered tissue.
• Humacyte's research and development expenses of $23.8 million in Q2 2024 are typical for a clinical-stage biotechnology company, and are comparable to companies like CRISPR Therapeutics and Editas Medicine, which are also investing heavily in R&D.

Management Changes

Stakeholder Impact

• The delay in FDA approval of the ATEV for vascular trauma may disappoint investors and patients awaiting this treatment.
• The positive Phase 3 results for ATEV in hemodialysis access are encouraging for patients with end-stage renal disease.
• The RMAT designation for ATEV in advanced peripheral artery disease is a positive development for patients with this condition.
• The company's financial losses may raise concerns among investors about its long-term viability.
• The company's employees may be impacted by the company's financial performance and regulatory outcomes.

Next Steps

• Humacyte will continue to work with the FDA to address their questions and complete the review of the ATEV BLA for vascular trauma.
• The company will present detailed results from the Phase 3 trial of ATEV in hemodialysis access at upcoming medical meetings.
• Humacyte will continue to advance its pipeline of ATEV products for various indications, including peripheral artery disease and coronary artery bypass grafts.
• The company will continue preclinical development of the BioVascular Pancreas (BVP) for type 1 diabetes.

Key Dates

Keywords

Humacyte, ATEV, FDA, Vascular Trauma, Hemodialysis, RMAT, Peripheral Artery Disease, Biologics License Application, Clinical Trial, Bioengineered Tissue